Infinant Health has filed a notice of an exempt offering of securities to raise $118,230,513.00 in New Funding.

July 21, 2026 Craig Etkin

According to filings with the U.S. Securities and Exchange Commission, Infinant Health is raising up to $118,230,513.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Infinant Health
Infinant Health, Inc is a privately held company committed to changing the trajectory of human health, one baby at a time, through our deep understanding of infant nutrition and the gut microbiome. Years of proprietary research into the role of breast milk and its impact on human development led to our groundbreaking discovery of B. infantis EVC001, a natural bacterial strain foundational to infant immune health. Unfortunately, B. infantis had been almost completely eradicated from infants in developed countries due to unintended consequences of modern medicine such as feeding and birthing practices. Now, there is a way to change that. What we found is that EVC001, our specific strain of B. infantis, is essential in developing a healthy microbiome and supporting healthy immune system function. We took that learning and developed INF108, a next-generation strain developed to prevent necrotizing enterocolitis (NEC) in pre-term infants. We believe the greatest chance to impact future health begins early, right after birtha once in a lifetime opportunity where rapid development and radical changes occur. By unlocking human nutrition’s full potential through introducing beneficial bacteria during early infancy, we can help build a foundation for better health. Investors in Infinant Health include Cargill and Bill & Melinda Gates Foundation, among others.

To learn more, visit https://www.infinanthealth.com/
LinkedIn: https://www.linkedin.com/company/infinant-health/

Contact:
Patrick Cormier, Chief Financial Officer
https://www.linkedin.com/in/patrick-cormier-cpa-73211417/